RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept
RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept
加拿大皇家銀行將Agios Pharmicals的目標股價從40美元上調至42美元，原因是鐮狀細胞病治療的第二階段試驗達到主要終點；表現保持跑贏大盤
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間